Featuring Sam Sather, Vice President, Clinical Pathways
“Every trial we do should be based on risk, especially human subject protection and data integrity,” says Sam Sather. Unfortunately, some practitioners minimize the importance of robust Risk Based Monitoring (RBM) programs, Sather says in our July 6, 2020 interview. “It’s the way we should be doing all trials, not just some trials,” Sather says. She also discusses the “downsides” of not incorporating an RBM mindset into trial conduct from the very beginning.